AIM: To investigate the impact of RAS and @entity817 mutations on the pattern of metastatic disease and @entity787 ( @entity787 ) production. METHODS: In this retrospective study, we investigated the impact of RAS and @entity817 mutational status on pattern of metastatic disease and @entity787 production. Only @entity1 presenting with a newly diagnosed metastatic @entity14 ( @entity14 ) were included. @entity1 ' characteristics, @entity5 location, site of metastatic disease and @entity787 at presentation were compared between those with and without RAS and @entity817 mutations. RESULTS: Among 174 @entity1 , mutations in @entity984 , @entity8497 and @entity817 were detected in 47%, 3% and 6% respectively. RAS mutations ( @entity984 and @entity8497 ) were more likely to be found in African American @entity1 (87% vs 13%; P value = 0.0158). RAS mutations were associated with a higher likelihood of a normal @entity787 (< 5 ng/mL) at presentation. @entity817 mutations were more likely to occur in females. We were not able to confirm any association between mutational status and site of metastatic disease at initial diagnosis. CONCLUSION: No association was found between RAS and @entity817 mutations and sites of metastatic disease at the time of initial diagnosis in our cohort. @entity1 with RAS mutations were more likely to present with @entity787 levels < 5 ng/mL. These findings may have clinical implications on surveillance strategies for RAS mutant @entity1 with earlier stages of @entity14 .

Impact of RAS and XXXX mutations on @entity787 production and pattern of colorectal metastases.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity787 :: ('1084', 'Gene') :: ['CEA', 'carcinoembryonic antigen'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer'] @entity8497 :: ('4893', 'Gene') :: ['NRAS'] @entity817 :: ('673', 'Gene') :: ['BRAF']
@entity817 :: (673,Gene) :: ['BRAF']
